ETON Stock Forecast & Price Target

Eton Pharmaceuticals is poised for strong growth and profitability, driven by the recent record top-line beat and raise, with management raising guidance to $145M for FY26 revenue and surpassing its prior co-pay program on Hemangeol already converting 95% of patients, adding further upside to this highly underappreciated company. Additionally, the undisclosed generic in the ultra rare metabolic disease market, the rapid HEMANGEOL conversion and organic pipeline growth in existing products and new product launches, and strategic business development initiatives position Eton for substantial value creation for its shareholders.

Eton Pharmaceuticals is a small specialty pharmaceutical company with a history of operating losses and limited capital. With its financial results hinging on the adoption of its assets and its heavy reliance on external funding, the company faces significant risks such as clinical, commercial, collaboration, dilution, legal, and intellectual property. While management guides ET-700 to peak sales of $100M+, the recent licensing of U.S. rights to ASN-001 appears to have potential to generate even larger revenues, making it an attractive addition to Eton's portfolio.